Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

NCT03423992 · clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Xuanwu Hospital, Beijing

Collaborators